Skip to main content
SpringerLink
Log in

Karboanhydrasehemmstoffe

  • Chapter
Glaukom

  • 51 Accesses

Zusammenfassung

Karboanhydrasehemmstoffe sind die z.Z. einzige Substanzgruppe, die bei der Dauertherapie des Glaukoms systemisch appliziert wird. Der Prototyp dieser Wirkstoffgruppe, das Acetazolamid, wurde als augendrucksenkendes Medikament 1954 [1] in die Ophthalmologie eingeführt und viel von unserem Verständnis ilber Karboanhydrasehemmstoffe zur Augeninnendrucksenkung geht auf Erfahrungen mit diesem Wirkstoff zurück. Andere, in den verschiedenen Ländern kommerziell verfügbare Karboanhydrasehemmstoffe sind Methazolamid, Diclofenamid und Ethoxzolamid. Den Karboanhydrasehemmstoffen ist der gleiche grundlegende Wirkungsmechanismus auf den Augeninnendruck gemeinsam. Auch die Neben-wirkungen sind identisch, jedoch quantitativ unter-schiedlich ausgeprägt. Es sollen deshalb die für die gesamte Substanzgruppe allgemein güen Aspekte zuerst besprochen werden, bevor auf spezielle Charakteristika der einzelnen Wirkstoffe eingegangen wird.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Becker, B: Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthal 37:13, 1954.

    PubMed  CAS  Google Scholar 

  2. Dobbs, PC, Epstein, DL, Anderson, PF: Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes. Invest Ophthal Vis Sci 18:867, 1979.

    PubMed  CAS  Google Scholar 

  3. Wistrand, PJ, Garg, LC: Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthal Vis Sci 18:802, 1979.

    PubMed  CAS  Google Scholar 

  4. Wistrand, PJ, Schenholm, M, Lonnerholm, G: Carbonic anhydrase isoenzymes CAI and CAII in the human eye. Invest Ophthal Vis Sci 27:419, 1986.

    PubMed  CAS  Google Scholar 

  5. Lutgen-Drecoll, E, Lonnerholm, G: Carbonic anhydrase distribution in the rabbit eye by light and electron microsco py. Invest Ophthal Vis Sci 21:782, 1981.

    Google Scholar 

  6. Lutjen-Drecoll, E, Lonnerholm, G, Eichhorn, M: Carbonic anhydrase distribution in the human and monkey eye by light and electron microscopy. Graefe’s Arch Ophthal 220:285, 1983.

    Article  CAS  Google Scholar 

  7. Krupin, T, Sly, WS, Whyte, MP, Dodgson, SJ: Failure of aceta zolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am J Ophthal 99:396, 1985.

    PubMed  CAS  Google Scholar 

  8. Dailey, RA, Brubaker, RF, Bourne, WM: The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthal 93:232, 1982.

    PubMed  CAS  Google Scholar 

  9. Yablonski, ME, Hayashi, M, Cook, DJ, et al: Fluorophotometric study of intravenous carbonic anhydrase inhibitors in rabbits. Invest Ophthal Vis Sci 28:2076, 1987.

    PubMed  CAS  Google Scholar 

  10. Berggren, L: Direct observation of secretory pumping in vitro of the rabbit eye ciliary processes. Influence of ion milieu and carbonic anhydrase inhibition. Invest Ophthal 3:266, 1964.

    PubMed  CAS  Google Scholar 

  11. Maren, TH: The rates of movement of Na+, Cl–, and HCO3– from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma. Invest Ophthal 15:356, 1976.

    PubMed  CAS  Google Scholar 

  12. Holland, MG, Gipson, CC: Chloride ion transport in the isolated ciliary body. Invest Ophthal 9:20, 1970.

    PubMed  CAS  Google Scholar 

  13. Bietti, G, Virno, M, Pecori-Giraldi, J, Pellegrino, N: Aceta zolamide, metabolic acidosis, and intraocular pressure. Am J Ophthal 80:360, 1975.

    PubMed  CAS  Google Scholar 

  14. Soser, M, Ogriseg, M, Kessler, B, Zirm, H: New findings concerning changes in intraocular pressure and blood acidosis after peroral application of acetazolamide. Klin Monatsbl Augenheilkd 176:88, 1980.

    Article  PubMed  CAS  Google Scholar 

  15. Benedikt, O, Zirm, M, Harnoncourt, K: Relations between metabolic acidosis and intraocular pressure after inhibition of carbonic anhydrase with acetazolamide. Graefe’s Arch Ophthal 190:247, 1974.

    CAS  Google Scholar 

  16. Friedman, Z, Krupin, T, Becker, B: Ocular and systemic effects of acetazolamide in nephrectomized rabbits. Invest Ophthal Vis Sci 23:209, 1982.

    PubMed  CAS  Google Scholar 

  17. Mehra, KS: Relationship of pH of aqueous and blood with acetazolamide. Ann Ophthal 11:63, 1979.

    CAS  Google Scholar 

  18. Flammer, J, Drance, SM: Effect of acetazolamide on the differential threshold. Arch Ophthal 101:1378, 1983.

    PubMed  CAS  Google Scholar 

  19. Thomas, RP, Riley, MW: Acetazolamide and ocular tension. Notes concerning the mechanism of action. Am J Ophthal 60:241, 1965.

    PubMed  CAS  Google Scholar 

  20. Peczon, JD, Grant, WM: Diuretic drugs in glaucoma. Am J Ophthal 66:680, 1968.

    PubMed  CAS  Google Scholar 

  21. Becker, B: The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, Diamox. Am J Ophthal 39:177, 1955.

    PubMed  CAS  Google Scholar 

  22. Macri, FJ: Acetazolamide and the venous pressure of the eye. Arch Ophthal 63:953, 1960.

    PubMed  CAS  Google Scholar 

  23. Bill, A: Effects of acetazolamide and carotid occlusion on the ocular blood flow in unanesthetized rabbits. Invest Ophthal 13:954, 1974.

    PubMed  CAS  Google Scholar 

  24. Walker, AM, Arrigg, C, Hertzmark, E, Epstein, DL: Carbonic anhydrase inhibitors induce elevations in human whole-blood zinc levels. Arch Ophthal 102:1785, 1984.

    PubMed  CAS  Google Scholar 

  25. Tsuboi, S, Pederson, J: Experimental retinal detachment: X. Effect of acetazolamide on vitreous fluorescein disappearance. Arch Ophthal 103:1557, 1985.

    PubMed  CAS  Google Scholar 

  26. Marmor, MF, Negi, A: Pharmacologic modifications of sub-retinal fluid absorption in the rabbit eye. Arch Ophthal 104:1674, 1986.

    PubMed  CAS  Google Scholar 

  27. Marmor, MF, Maack, T: Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthal Vis Sci 23:121, 1982.

    PubMed  CAS  Google Scholar 

  28. Cox, SN, Hay, E, Bird, AC: Treatment of chronic macularedema with acetazolamide. Arch Ophthal 106:1190, 1988.

    PubMed  CAS  Google Scholar 

  29. Fishman, G A, Gilbert, LD, Fiscella, RG, et al: Acetazolamide for treatment of chronic macular edema in retinitis pig-mentosa. Arch Ophthal 107:1445, 1989.

    PubMed  CAS  Google Scholar 

  30. Friedenwald, JS: Current studies on acetazolamide (Diamox) and aqueous humor flow. Am J Ophthal 40:139, 1955.

    PubMed  CAS  Google Scholar 

  31. Becker, B: Misuse of acetazolamide. Am J Ophthal 43:799, 1957.

    Google Scholar 

  32. Goren, SB, Newell, FW, O’Toole, JJ: The localization of Dia-mox-S35 in the rabbit eye. Am J Ophthal 51:87, 1961.

    PubMed  CAS  Google Scholar 

  33. Block, ER, Rostand, RA: Carbonic anhydrase inhibition inglaucoma: hazard or benefit for the chronic lunger? Surv Ophthal 23:169, 1978.

    Article  CAS  Google Scholar 

  34. Margo, CE: Acetazolamide and advanced liver disease. Am J Ophthal 101:611, 1986.

    PubMed  CAS  Google Scholar 

  35. Heller, I, Halevy, J, Cohen, S, Theodor, E: Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intern Med 145:1815, 1985.

    Article  PubMed  CAS  Google Scholar 

  36. Epstein, DL, Grant, WM: Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthal 95:1378, 1977.

    PubMed  CAS  Google Scholar 

  37. Wallace, TR, Fraunfelder, FT, Petursson, GJ, Epstein, DL: Decreased libido-a side effect of carbonic anhydrase inhibitor. Ann Ophthal 11:1563, 1979.

    PubMed  CAS  Google Scholar 

  38. Arrigg, CA, Epstein, DL, Giovanoni, R, Grant, WM: The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects. Arch Ophthal 99:1969, 1981.

    PubMed  CAS  Google Scholar 

  39. Anderson, CJ, Kaufman, PL, Sturm, RJ: Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthal 86:516, 1978.

    PubMed  CAS  Google Scholar 

  40. Spaeth, GL: Potassium, acetazolamide, and intraocular pressure. Arch Ophthal 78:578, 1967.

    PubMed  CAS  Google Scholar 

  41. Critchlow, AS, Freeborn, SF, Roddie, RA: Potassium supplements during treatment of glaucoma with acetazolamide. Br Med J 289:21, 1984.

    Article  CAS  Google Scholar 

  42. Kass, MA, Kolker, AE, Gordon, M, et al: Acetazolamide and urolithiasis. Ophthalmology 88:261, 1981.

    PubMed  CAS  Google Scholar 

  43. Constant, MA, Becker, B: The effect of carbonic anhydrase inhibitors on urinary excretion of citrate by humans. Am J Ophthal 49:929, 1960.

    PubMed  CAS  Google Scholar 

  44. Grant, WM: Antiglaucoma drugs: problems with carbonic anhydrase inhibitors. In: Symposium on Ocular Therapy, vol. 6, Leopold, IH, ed. CV Mosby, St. Louis, 1972, p. 19.

    Google Scholar 

  45. Simpson, DP: Effect of acetazolamide on citrate excretion in the dog. Am J Physiol 206:883, 1964.

    PubMed  CAS  Google Scholar 

  46. Kondo, T, Sakaue, E, Koyama, S, et al: Urolithiasis during treatment of carbonic anhydrase inhibitors. Folia Ophthal Jap 19:576, 1968.

    PubMed  CAS  Google Scholar 

  47. Parfitt, AM: Acetazolamide and renal stone formation. Lancet 2:153, 1970.

    Article  PubMed  CAS  Google Scholar 

  48. Persky, L, Chambers, D, Potts, A: Calculus formation and ureteral colic following acetazolamide (Diamox) therapy. JAMA 161:1625, 1956.

    CAS  Google Scholar 

  49. Charron, RC, Feldman, F: Acetazolamide therapy with renal complications. Can J Ophthal 9:282, 1974.

    CAS  Google Scholar 

  50. Wisch, N, Fischbein, FI, Siegel, R, et al: Aplastic anemia resulting from the use of carbonic anhydrase inhibitors. Am J Ophthal 75:130, 1973.

    PubMed  CAS  Google Scholar 

  51. Gangitano, JL, Foster, SH, Contro, RM: Nonfatal methazo-lamide-induced aplastic anemia. Am J Ophthal 86:138, 1978.

    PubMed  CAS  Google Scholar 

  52. Werblin, TP, Pollack, IP, Liss, RA: Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology 87:350, 1980.

    PubMed  CAS  Google Scholar 

  53. Fraundfelder, FT, Meyer, SM, Bagby, GC Jr, Dreis, MW: Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthal 100:79, 1985.

    Google Scholar 

  54. Mogk, LG, Cyrlin, MN: Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 95:768, 1988.

    PubMed  CAS  Google Scholar 

  55. Zimran, A, Beutler, E: Can the risk of acetazolamide-in-duced aplastic anemia be decreased by periodic monitoring of blood cell counts? Am J Ophthal 104:654, 1987.

    PubMed  CAS  Google Scholar 

  56. Bovino, JA, Marcus, DF: The mechanism of transient myo-pia induced by sulfonamide therapy. Am J Ophthal 94:99, 1982.

    PubMed  CAS  Google Scholar 

  57. Weiss, IS: Hirsutism after chronic administration of acetazo-lamide. Am J Ophthal 78:327, 1974.

    PubMed  CAS  Google Scholar 

  58. Maren, TH: Teratology and carbonic anhydrase inhibition. Arch Ophthal 85:1, 1971.

    PubMed  CAS  Google Scholar 

  59. Worsham, GF, Beckman, EN, Mitchell, EH: Sacrococcygeal teratoma in a nconate. JAMA 240:251, 1978.

    Article  PubMed  Google Scholar 

  60. Hargett, NA, Ritch, R, Mardirossian, J, et al: Inadvertent substitution of acetohexamide for acetazolamide. Am J Ophthal 84:580, 1977.

    PubMed  CAS  Google Scholar 

  61. Shrader, CE, Thomas, JV, Simmons, RJ: Relationship of patient age and tolerance to carbonic anhydrase inhibitors. Am J Ophthal 96:730, 1983.

    PubMed  CAS  Google Scholar 

  62. Lichter, PR: Reducing side effects of carbonic anhydrase in hibitors. Ophthalmology 88:266, 1981.

    PubMed  CAS  Google Scholar 

  63. Friedland, BR, Mallonee, J, Anderson, DR: Short-term dose response characteristics of acetazolamide in man. Arch Ophthal 95:1809, 1977.

    PubMed  CAS  Google Scholar 

  64. Lichter, PR, Musch, DC, Medzihradsky, F, Standardi, CL: In traocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthal 107:11, 1989.

    PubMed  CAS  Google Scholar 

  65. Berson, FG, Epstein, DL, Grant, WM, et al: Acetazolamide dosage forms in the treatment of glaucoma. Arch Ophthal 98:1051,1 980.

    Google Scholar 

  66. Joyce, PW, Mills, KB, Richardson, T, Mawer, GE: Equivalence of conventional and sustained release oral dosage for mulations of acetazolamide in primary open angle glaucoma. Br J Clin Pharmacol 27:597, 1989.

    PubMed  CAS  Google Scholar 

  67. Yablonski, ME, Maren, TH, Hayashi, M, et al: Enhancement of the ocular hypotensive effect of acetazolamide by diflunisal. Am J Ophthal 106:332, 1988.

    Article  PubMed  CAS  Google Scholar 

  68. Havener, WH: Ocular Pharmacology, 4th ed. CV Mosby, St. Louis, 1978, p.475.

    Google Scholar 

  69. Alward, PD, Wilensky, JT: Determination of acetazolamide compliance in patients with glaucoma. Arch Ophthal 99:1973, 1981.

    PubMed  CAS  Google Scholar 

  70. Theeuwes, F, Bayne, W, McGuire, J: Gastrointestinal therapeutic system for acetazolamide. Efficacy and side effects. Arch Ophthal 96:2219, 1978.

    PubMed  CAS  Google Scholar 

  71. Lichter, PR, Newman, LP, Wheeler, NC, Beall, OV: Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthal 85:495, 1978.

    PubMed  CAS  Google Scholar 

  72. Ellis, PP, Price, PK, Kelmenson, R, Rendi, MA: Effectiveness of generic acetazolamide. Arch Ophthal 100:1920, 1982.

    PubMed  CAS  Google Scholar 

  73. Maren, TH, Haywood, JR, Chapman, SK, Zimmerman, TJ: The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthal Vis Sci 16:730, 1977.

    PubMed  CAS  Google Scholar 

  74. Stone, RA, Zimmerman, TJ, Shin, DH, et al: Low-dose methazolamide and intraocular pressure. Am J Ophthal 83:674, 1977.

    PubMed  CAS  Google Scholar 

  75. Dahlen, K, Epstein, DL, Grant, WM, et al: A repeated dose-response study of methazolamide in glaucoma. Arch Ophthal 96:2214, 1978.

    PubMed  CAS  Google Scholar 

  76. Merkle, W: Effect of methazolamide on the intraocular pressure of patients with open-angle glaucoma. Klin Monatsbl Augenheilkd 176:181, 1980.

    Article  PubMed  CAS  Google Scholar 

  77. Zimmerman, TJ: Acetazolamide and methazolamide. Ann Ophthal 10:509, 1978.

    Google Scholar 

  78. Becker, B: Use of methazolamide (Neptazane) in the therapy of glaucoma. Comparison with acetazolamide (Diamox). Am J Ophthal 49:1307, 1960.

    PubMed  CAS  Google Scholar 

  79. Ellis, PP: Urinary calculi with methazolamide therapy. Doc Ophthal 34:137, 1973.

    Article  CAS  Google Scholar 

  80. Shields, MB, Simmons, RJ: Urinary calculus during metha zolamide therapy. Am J Ophthal 81:622, 1976.

    PubMed  CAS  Google Scholar 

  81. Stein, A, Pinke, R, Krupin, T, et al: The effect of topically administered carbonic anhydrase inhibitors on aqueous humordynamics in rabbits. Am J Ophthal 95:222, 1983.

    Article  PubMed  CAS  Google Scholar 

  82. Flach, AJ, Peterson, JS, Seligmann, KA: Local ocular hypotensive effect of topically applied acetazolamide. Am J Ophthal 98:66, 1984.

    Article  PubMed  CAS  Google Scholar 

  83. Friedman, Z, Allen, RC, Raph, SM: Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthal 103:963, 1985.

    PubMed  CAS  Google Scholar 

  84. Edelhauser, HF, Maren, TH: Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthal 106:1110, 1988.

    PubMed  CAS  Google Scholar 

  85. Bar-Ilan, A, Pessah, NI, Maren, TH: The effects of carbonic anhydrase inhibitors on aqueous humor chemistry and dynamics. Invest Ophthal Vis Sci 25:1198, 1984.

    PubMed  CAS  Google Scholar 

  86. Lewis, RA, Schoenwald, RD, Eller, MG, et al: Ethoxzolamide analogue gel. A topical carbonic anhydrase inhibitor. Arch Ophthal 102:1821, 1984.

    PubMed  CAS  Google Scholar 

  87. Bar-Ilan, A, Pessah, NI, Maren, TH: Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645, 151. J Ocular Pharmacol 2:109, 1986.

    Article  CAS  Google Scholar 

  88. Lewis, RA, Schoenwald, RD, Barfknecht, CF, Phelps, CD: Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension. Arch Ophthal 104:842, 1986.

    PubMed  CAS  Google Scholar 

  89. Kalina, PH, Shetlar, DJ, Lewis, RA, et al: 6-amino-2-benzo-thiazolesulfonamide. The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology 95:772, 1988.

    PubMed  CAS  Google Scholar 

  90. Sugrue, MF, Gautheron, P, Grove, J, et al: MK-927: a topically effective ocular hypotensive carbonic anhydrase (CA) in hibitor in rabbits. Invest Ophthal Vis Sci (suppl) 29:81, 1988.

    Google Scholar 

  91. Wang, RF, Serle, JB, Podos, SM, Sugrue, MF: The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys. Curr Eye Res 9:163, 1990.

    Article  PubMed  CAS  Google Scholar 

  92. Lippa, EA, von Denffer, HA, Hofmann, HM, Brunner-Ferber, FL: Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor. Arch Ophthal 106:1694, 1988.

    PubMed  CAS  Google Scholar 

  93. Bron, AM, Lippa, EA, Hofmann, HM, et al: MK-927: a topically effective carbonic anhydrase inhibitor in patients. Arch Ophthal 107:1143, 1989.

    PubMed  CAS  Google Scholar 

  94. Higginbotham, EJ, Kass, MA, Lippa, EA, et al: MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action. Arch Ophthal 108:65, 1990.

    PubMed  CAS  Google Scholar 

  95. Serle, JB, Lustgarten, JS, Lippa, EA, et al: MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility. Arch Ophthal 108:838, 1990.

    PubMed  CAS  Google Scholar 

  96. Sugrue, MF, Mallorga, P, Schwam, H, et al: A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 9:607, 1990.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophtalmology, Duke University Medical Center, Durham, NC, 27710, USA

    Prof. Dr. M. Bruce Shields

  2. Direktor der Universitäts-Augenklinik Köln, Joseph-Stelzmann-Straße 9, 50931, Köln, Deutschland

    Prof. Dr. Günter Karl Krieglstein

Authors
  1. Prof. Dr. M. Bruce Shields
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Günter Karl Krieglstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shields, M.B., Krieglstein, G.K. (1993). Karboanhydrasehemmstoffe. In: Glaukom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77053-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77053-1_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77054-8

  • Online ISBN: 978-3-642-77053-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation